ArticleFrontiers in pharmacology2025
Hsa_circ_0002238 promotes the malignant behavior of colorectal cancer.
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Colorectal cancer (CRC) is one of the most common and deadly cancers worldwide. Circular RNAs (circRNAs) have emerged as crucial players in the onset and progression of CRC. This research aims to investigate the expression levels of a novel circRNA, hsa_circ_0002238, in CRC and to explore its association with alterations in CRC functional phenotypes. Methods: High-throughput RNA sequencing identified abnormal circRNA expressions, and qRT-PCR validated hsa_circ_0002238 expression. The relationship between hsa_circ_0002238 expression and the clinical data was analyzed by student's t-test. Fluorescence Results: Our findings showed that hsa_circ_0002238 was significantly overexpressed in both CRC cell lines and tumor tissues. The expression level of hsa_circ_0002238 correlates with patient gender (p = 0.017) and shows significant diagnostic value (AUC = 0.765, 95%CI: 0.618-0.913, p = 0.004). At a relative expression level of 5.836, it achieves high sensitivity (50%) and specificity (100%). This upregulation promotes cellular proliferation, migration, invasion while inhibiting apoptosis within CRC cells. Conclusion: Our research demonstrates that hsa_circ_0002238 expression significantly enhances CRC proliferation, migration, invasion, EMT process, PI3K/AKT signaling pathway while inhibiting apoptosis. Additionally, a preliminary association between hsa_circ_0002238 levels and patient gender was found, suggesting its potential as a diagnostic marker for CRC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.